Loading
A phase 2 trial of Encorafenib, Binimetinib in non-small-cell lung cancer and small-cell lung cancer, run by Pierre Fabre Medicament, active and no longer recruiting.
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05195632 by Pierre Fabre Medicament, with 63 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2024-05-27. Interventions recorded: Encorafenib, Binimetinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pierre Fabre, Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, BRAF V600E-mutant non-small-cell lung cancer, Encorafenib.
Shares Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, BRAF V600E-mutant non-small-cell lung cancer, Encorafenib, Small-molecule kinase inhibitors.
Shares A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pierre Fabre, Non-small-cell lung cancer.
Shares Binimetinib, Encorafenib, Small-molecule kinase inhibitors.
Shares Binimetinib, Encorafenib.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/